Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$7.34 +1.8%	$6.36	$4.64 ▼ $61.90	$89.82M	3.19	359,301 shs	65,451 shs
GALT Galectin Therapeutics	$1.28 -3.0%	$1.41	$0.73 ▼ $3.28	$83.40M	0.62	317,590 shs	295,829 shs
KALA KALA BIO	$3.67 +14.0%	$4.50	$2.92 ▼ $11.20	$23.68M	-1.91	94,997 shs	109,077 shs
VIRI Virios Therapeutics	$5.32 -3.1%	$5.22	$0.13 ▼ $1.04	$102.45M	1.58	1.05 million shs	140,614 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	0.00%	+13.80%	+21.72%	-13.75%	-83.37%
GALT Galectin Therapeutics	0.00%	-7.25%	-7.25%	-9.22%	-58.17%
KALA KALA BIO	0.00%	+7.31%	+6.38%	-56.21%	-45.22%
VIRI Virios Therapeutics	-3.10%	+16.67%	+42.63%	-13.21%	+1,208.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBP Corbus Pharmaceuticals	4.4652 of 5 stars	4.6	3.0	4.7	2.4	1.7	0.0
GALT Galectin Therapeutics	1.4005 of 5 stars	3.0	0.0	0.0	3.9	1.7	0.0
KALA KALA BIO	3.6902 of 5 stars	3.5	1.0	4.4	3.6	0.0	0.6
VIRI Virios Therapeutics	0.1624 of 5 stars	1.3	0.0	0.0	0.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBP Corbus Pharmaceuticals	3.10	Buy	$50.88	593.12% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	759.38% Upside
KALA KALA BIO	3.00	Buy	$15.00	308.72% Upside
VIRI Virios Therapeutics	2.50	Moderate Buy	$3.00	-43.61% Downside

Current Analyst Ratings Breakdown

Latest KALA, GALT, VIRI, and CRBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/7/2025	CRBP Corbus Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$65.00 ➝ $58.00
5/7/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $56.00
5/7/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
4/4/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/2/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/12/2025	CRBP Corbus Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$51.00
3/12/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $50.00
3/11/2025	CRBP Corbus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $53.00
2/28/2025	CRBP Corbus Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
2/18/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	($1.56) per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.01) per share	N/A
KALA KALA BIO	$3.89M	6.09	N/A	N/A	$2.79 per share	1.32
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBP Corbus Pharmaceuticals	-$44.60M	-$4.22	N/A	N/A	N/A	N/A	-42.28%	-32.92%	8/5/2025 (Estimated)
GALT Galectin Therapeutics	-$41.07M	-$0.72	N/A	N/A	N/A	N/A	N/A	-163.15%	5/21/2025 (Estimated)
KALA KALA BIO	-$42.20M	-$8.24	N/A	N/A	N/A	N/A	-448.61%	-69.37%	8/5/2025 (Estimated)
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A

Latest KALA, GALT, VIRI, and CRBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/6/2025	Q1 2025	CRBP Corbus Pharmaceuticals	-$1.26	-$1.39	-$0.13	-$1.39	N/A	N/A
3/31/2025	Q4 2024	GALT Galectin Therapeutics	-$0.16	-$0.19	-$0.03	-$0.19	N/A	N/A
3/28/2025	Q4 2024	KALA KALA BIO	-$2.28	-$1.74	+$0.54	-$1.74	N/A	N/A
3/11/2025	Q4 2024	CRBP Corbus Pharmaceuticals	-$1.02	-$0.78	+$0.24	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBP Corbus Pharmaceuticals	N/A	13.84	13.84
GALT Galectin Therapeutics	N/A	1.13	1.13
KALA KALA BIO	3.18	2.15	2.15
VIRI Virios Therapeutics	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBP Corbus Pharmaceuticals	64.64%
GALT Galectin Therapeutics	11.68%
KALA KALA BIO	24.61%
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
CRBP Corbus Pharmaceuticals	3.60%
GALT Galectin Therapeutics	50.10%
KALA KALA BIO	8.32%
VIRI Virios Therapeutics	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBP Corbus Pharmaceuticals	40	12.24 million	11.69 million	Optionable
GALT Galectin Therapeutics	9	63.18 million	31.32 million	Optionable
KALA KALA BIO	30	6.45 million	5.58 million	Not Optionable
VIRI Virios Therapeutics	5	19.26 million	16.91 million	Optionable

KALA, GALT, VIRI, and CRBP Headlines

Recent News About These Companies

Virios Therapeutics (NASDAQ:VIRI) Stock Price Down 1.5% - Time to Sell?

May 12, 2025 | marketbeat.com

Virios Therapeutics (NASDAQ:VIRI) Shares Up 14.5% - Here's What Happened

April 21, 2025 | marketbeat.com

Dogwood Therapeutics Inc (DWTX)

March 16, 2025 | investing.com

Dogwood prices 578,950 shares at $8.26 in registered direct offering

March 13, 2025 | markets.businessinsider.com

Dogwood announces conversion of existing $19.5M in debt to equity

March 12, 2025 | markets.businessinsider.com

DWTX Stock trading resumes

February 11, 2025 | markets.businessinsider.com

Dogwood Therapeutics, Inc. (DWTX)

February 2, 2025 | finance.yahoo.com

DWTX Stock trading halted, volatility trading pause

January 28, 2025 | markets.businessinsider.com

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

January 23, 2025 | msn.com

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

January 22, 2025 | markets.businessinsider.com

Polluted communities hold their breath as companies struggle with California’s diesel truck ban

December 10, 2024 | apnews.com

Dogwood Therapeutics faces potential Nasdaq delisting

November 24, 2024 | uk.investing.com

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

November 18, 2024 | markets.businessinsider.com

Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

November 18, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary

November 16, 2024 | benzinga.com

DWTX: Phase 2 Long COVID Results Expected Soon

November 12, 2024 | msn.com

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

November 10, 2024 | markets.businessinsider.com

Dogwood Therapeutics Reports Q3 2024 Financial Results

November 9, 2024 | markets.businessinsider.com

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 8, 2024 | markets.businessinsider.com

Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 31, 2024 | finanznachrichten.de

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA, GALT, VIRI, and CRBP Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

$7.34 +0.13 (+1.80%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$7.48 +0.15 (+1.98%)

As of 05/16/2025 07:22 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Galectin Therapeutics NASDAQ:GALT

$1.28 -0.04 (-3.03%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$1.27 -0.01 (-0.39%)

As of 05/16/2025 04:22 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

KALA BIO NASDAQ:KALA

$3.67 +0.45 (+13.98%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$3.76 +0.09 (+2.45%)

As of 05/16/2025 07:40 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Virios Therapeutics NASDAQ:VIRI

$5.32 -0.17 (-3.10%)

As of 05/16/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time